New trials, publications, preprints and grants on this target, month by month.
Trial
CAR-T Immunotherapy Targeting CD19- ALL
1 Jul 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR-T Cells Targeting B Cell Lymphomas
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
1 May 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
1 Mar 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
1 Feb 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Study Of KITE-753 in R/R B-Cell ALL
31 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
7 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
1 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Persistent Coronavirus Disease 2019 (COVID-19) in Patients With Malignant Lymphoma Treated With Anti-CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases.
2 Nov 2026· Respirology case reports· PUBMED
Trial
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
1 Nov 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.
1 Nov 2026· The Lancet. Oncology· PUBMED
Publication
Subcutaneous panniculitis-like T cell lymphoma in a patient with multiple sclerosis during anti-CD20 therapy: a case report.
30 Oct 2026· Journal of neurology· PUBMED
Publication
Anti-CD20 mediated B cell depletion exerts a distinct influence on T cell immunity by decreasing effector memory CD4 Th17 and Th1.17 subsets in multiple sclerosis.
29 Oct 2026· Immunobiology· PUBMED
Publication
Is it time for anti-CD20 discontinuation in multiple sclerosis? Cumulative risk or cumulative uncertainty.
22 Oct 2026· Frontiers in immunology· PUBMED
Trial
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
20 Oct 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publication
Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial.
17 Oct 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Publication
A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis.
17 Oct 2026· Brain : a journal of neurology· PUBMED
Publication
Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial.
16 Oct 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Trial
Prospective ctDNA Testing in Large B-Cell Lymphoma
15 Oct 2026· NA · RECRUITING· CTGOV
Publication
Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study.
15 Oct 2026· Journal of neurology· PUBMED
Publication
Correction: Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis.
15 Oct 2026· Rheumatology advances in practice· PUBMED
Trial
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
10 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Switching Beyond Rituximab in Primary Glomerular Diseases: A Systematic Review of Within-Patient Efficacy and Safety of Non-Rituximab Anti-CD20 Antibodies.
10 Oct 2026· Antibodies (Basel, Switzerland)· PUBMED
Publication
Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review.
9 Oct 2026· Neurology and therapy· PUBMED
Publication
T-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis.
1 Oct 2026· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publication
Anti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis.
1 Oct 2026· European journal of neurology· PUBMED
Trial
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy
30 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison.
30 Sept 2026· Multiple sclerosis and related disorders· PUBMED
Publication
Case Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis.
29 Sept 2026· Frontiers in immunology· PUBMED
Publication
The influence of anti-CD20-directed B cell depletion across different agents on Epstein-Barr virus-specific humoral and cellular immunity in patients with multiple sclerosis.
28 Sept 2026· Journal of neuroinflammation· PUBMED